|
 The move comes after the U.S Food and Drug Administration (FDA)
regulator had also approved the injectable antibody drug in March.
The product is sold as Dupixent.
Atopic dermatitis is a chronic type of skin inflammation also known
as eczema, which in severe cases causes constant, and often
unbearable, itching.
A human monoclonal antibody, Dupixent is designed to specifically
inhibit two key proteins which are believed to be major drivers of
the disease.
Sanofi plans to submit an application to the FDA for a use of
dupilumab in asthma by the end of the year and hinted recently at a
possible use of the drug in nasal polyps.
Analysts on average expect Dupixent to reach annual sales of 4.7
billion euros ($5.53 billion) by 2023, according to Thomson Reuters
data.
Shares of Regeneron and Sanofi slid earlier this month after
late-stage trial data for dupilumab in asthma fell short of investor
expectations. Analysts said the data appeared less impressive than
the drug's mid-stage data.
[to top of second column] |
Investors had also expressed disappointment with the sales take-up
of Dupixent when Sanofi published its second quarter-results in
July, although but Sanofi expressed confidence that the drug would
sell well.
(Reporting by Matthias Blamont; Editing by Sudip Kar-Gupta)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
